CABOTEGRAVIR

An inhibitor of HIV integrase

Dosage Forms

▼

Tablet

30 mg

Prolonged-release suspension for injection

200 mg per 1 ml

Uses

▼
  • HIV/AIDS prevention

Dose and Duration

▼
HIV-1 infection[in combination with rilpivirine prolonged release injection]

By intramuscular injection

Adult: Initially 600mg for 1 dose at month 2,then maintenance 400mg every month from month 3 onwards, maintenance injections may be administered up to 7 days before or after the scheduled dose.

Side Effects

▼
  • Anxiety
  • Dizziness
  • Malaise
  • Myalgia
  • Weight gain
  • Skin reactions

Contra-indications

▼
  • Co-infection with hepatitis B or C has risk factor for virological failure
  • BMI of 30kg/m² or more

Pregnancy

▼
  • Do not use

Breast-feeding

▼
  • Do not use

⚠️ Caution

▼
  • Use with caution in patients with HIV-1 subtype A6/A1 or BMI of 30kg/m² or more, if treatment history uncertain and pre-treatment resistance analyses absent